Revenue Within Guidance and Continued Demand
Q2 revenue of $216 million came in within guidance; total revenue increased 1% year-over-year, driven by medical (+2%) and industrial (+1%). Medical represented $156M (72% of total) and Industrial $60M (28%).
Strong Non-GAAP Margin and EPS Execution
Non-GAAP gross margin was 34% (at the high end of guidance) and non-GAAP EPS was $0.21, in-line with expectations.
Improved Capital Structure via Debt Refinancing
Completed debt refinancing in the quarter, reducing outstanding debt and annual interest expense; gross debt $351M, cash & marketable securities $88M, net debt ~$263M — supporting greater financial flexibility.
Profitability Metrics and Leverage
Adjusted EBITDA was $27M (12% of sales) for the quarter; trailing 12‑month adjusted EBITDA was $118M and net debt leverage was ~2.2x adjusted EBITDA.
Medical Product Momentum — CT and Photon Counting
CT and radiography exceeded the company’s 5-quarter sales trend; CT remains a key growth driver. Photon-counting technology sales momentum remained strong with active engagement: 2 CT OEMs plus discussions with 8 additional OEMs across modalities.
Industrial Segment Traction and Pipeline
Industrial saw continued demand for tubes, linear accelerators, detectors and cargo security systems; company reported multiple new cargo inspection deals (including mobile systems and car scanners) and expects industrial to be an increasing driver of growth and margin expansion.
Regional Strength in Americas and APAC
Americas grew 13% YoY and APAC grew 8% YoY, providing geographic pockets of strong demand.
Manufacturing Ramp in India Expected to Improve Margins
Detector factory in India completed and ramping (utilization currently low but expected to be materially utilized by year-end); company expects this to convert current gross margin and OpEx headwinds into tailwinds as utilization rises toward ~60–70%.
Forward Guidance and Return to Annual Guidance Practice
Company provided FY26 revenue guidance of $860M–$880M (second half revenue expected to be ~+3% YoY) and non-GAAP EPS guidance of $0.80–$1.00; management resumed providing an annual view citing improved visibility.